India to Denmark: Albendazole Export Trade Route

To import finished pharmaceutical formulations containing Albendazole into Denmark, compliance with the European Medicines Agency (EMA) and the Danish Medicines Agency (Lægemiddelstyrelsen) regulations is mandatory. The primary pathway for market authorization is the centralized procedure managed by the EMA, which grants approval valid across all European Union (EU) member states, including Denmark.

Dossier Submission Format: Applicants must submit a comprehensive dossier in the Common Technical Document (CTD) or electronic Common Technical Document (eCTD) format. This dossier encompasses five modules:

1. 1Administrative and product information
2. 2Summaries of quality, safety, and efficacy data
3. 3Quality (pharmaceutical documentation)
4. 4Non-clinical study reports
5. 5Clinical study reports

Approval Timelines: The EMA's evaluation process for a marketing authorization application (MAA) typically spans 210 days, excluding any clock stops for additional information requests. This timeline may extend if supplementary data or clarifications are required.

Product Registration Fees: The EMA imposes fees for processing MAAs, which vary based on the application type and the applicant's status (e.g., small or medium-sized enterprise). As of March 2026, the standard fee for a full MAA is approximately €296,000. Applicants should consult the EMA's official fee schedule for precise and current figures.

GMP Inspection Requirements: Manufacturing facilities outside the EU, including those in India, must undergo Good Manufacturing Practice (GMP) inspections conducted by EU authorities. These inspections assess compliance with EU GMP standards. A successful inspection results in the issuance of a GMP certificate, a prerequisite for product approval. In 2024, the EMA reported that 10 GMP inspections led to non-compliance statements, underscoring the critical importance of adherence to GMP standards. (ema.europa.eu)

Indian manufacturers exporting Albendazole formulations to Denmark must comply with EU GMP standards. This entails obtaining a GMP certificate from an EU authority, confirming that the manufacturing processes meet EU requirements.

Current Approvals and Inspections: In 2024, EU authorities issued 105 GMP certificates to Indian facilities, reflecting a commitment to maintaining high manufacturing standards. However, the same year saw five non-compliance statements issued to Indian manufacturers, indicating areas requiring improvement. (ema.europa.eu)

Recent Regulatory Actions: Between 2024 and 2025, several Indian pharmaceutical companies faced regulatory actions due to GMP violations. For instance, in early 2025, Jagsonpal Pharmaceuticals and Tyche Industries received Warning Letters and were placed under Import Alert 66-40 for GMP failures, including lapses in process validation and falsified temperature data. Additionally, in June 2025, Sun Pharmaceutical Industries' Halol facility was classified as Official Action Indicated (OAI) following an inspection, leading to an import alert.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to Denmark:

1. Revised Variations Framework & Mandatory eAF (January 2026): The EMA introduced an updated Variations Framework, streamlining the process for post-approval changes. This includes mandatory use of the electronic Application Form (eAF), enhancing efficiency and consistency in submissions.

2. GMP Annex Revisions (February 2026): The EMA initiated revisions to GMP guidelines, including Annex 6 (Manufacture of Medicinal Gases) and Annex 15 (Qualification and Validation). These updates aim to align with current industry practices and technological advancements, affecting manufacturers exporting to the EU. (ema.europa.eu)

3. Schedule M Amendment in India (December 2023): India's Ministry of Health and Family Welfare revised Schedule M of the Drugs Rules, aligning Indian GMP standards more closely with WHO-GMP and international norms. This amendment mandates enhanced quality controls across manufacturing processes. However, implementation challenges persist, particularly among Micro, Small, and Medium Enterprises (MSMEs), with many missing compliance deadlines.

These developments underscore the dynamic regulatory landscape affecting pharmaceutical exports from India to Denmark. Manufacturers must stay informed and adapt to these changes to ensure continued market access.

Albendazole is an anthelmintic medication used to treat various parasitic worm infestations. In Denmark, the demand for Albendazole formulations is influenced by factors such as disease prevalence, healthcare spending, and public health initiatives. While specific market size data for Albendazole in Denmark for 2024-2025 is not readily available, the global Albendazole market was valued at approximately $11.67 billion in 2024 and is projected to reach $12.81 billion in 2025.

Denmark's healthcare system provides universal coverage, ensuring access to essential medications, including Albendazole formulations. The country imports Albendazole formulations to meet domestic demand, with India being a significant supplier. Domestic manufacturing of Albendazole formulations in Denmark is limited, leading to reliance on imports to fulfill market needs.

Denmark, as a member of the European Union, applies the EU's common external tariff. Pharmaceutical products classified under HS code 30049099, including Albendazole formulations, are subject to a Most-Favored-Nation (MFN) import duty rate of 0%. Additionally, a Value-Added Tax (VAT) of 25% is applied to all goods sold in Denmark, including imported pharmaceuticals.

There are no specific Free Trade Agreements (FTAs) between India and Denmark that affect pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on Albendazole formulations imported from India into Denmark.

India is a major supplier of Albendazole formulations to Denmark, accounting for approximately 7.3% of India's total Albendazole formulation exports, valued at $5.3 million USD across 47 shipments. The primary exporters from India include MEDOPHARM and MEPRO PHARMACEUTICALS PRIVATE LIMITED. The main buyer in Denmark is the UNICEF Supply Division.

Other countries supplying Albendazole formulations to Denmark include the United States. In July 2024, Denmark imported 1,913 kilograms of medicaments under HS code 30049000 from the United States, valued at $661,144 USD.

India's pricing for Albendazole formulations is competitive compared to other suppliers, contributing to its significant share in Denmark's import market. The cost-effectiveness of Indian pharmaceutical products, combined with established supply chains, positions India as a key player in meeting Denmark's demand for Albendazole formulations.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. This extensive manufacturing base includes a significant capacity for producing finished dosage forms containing Albendazole, such as tablets, capsules, and syrups. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of December 2024, numerous Indian facilities producing Albendazole formulations have received WHO-GMP certification, ensuring compliance with international quality standards. Additionally, companies like Alembic Pharmaceuticals have secured US FDA approvals for their Albendazole tablets, reflecting adherence to stringent regulatory requirements.

When comparing Albendazole formulation exports, India offers a competitive advantage over China and the European Union (EU) in terms of cost and quality. Indian manufacturers provide finished dosage forms at a lower price per unit due to efficient production processes and lower labor costs. The quality of Indian Albendazole formulations is recognized globally, with multiple facilities holding WHO-GMP and US FDA certifications. In contrast, while the EU produces high-quality branded generics, the cost is typically higher, and local manufacturers in Denmark may not have the same economies of scale, leading to increased prices. Regulatory acceptance of Indian formulations in Denmark is facilitated by these international certifications, and Indian suppliers have demonstrated a reliable supply track record.

The India-Denmark supply chain for Albendazole formulations is robust, supported by substantial manufacturing capacities. Indian facilities are equipped with advanced packaging and cold chain capabilities to ensure product integrity during transit. Recent inspections, such as the US FDA's approval of Alembic Pharmaceuticals' Albendazole tablets in September 2024, indicate compliance with international regulatory standards. While some Indian manufacturers have faced regulatory challenges, many have implemented corrective actions and expanded capacities to meet global demand. For instance, Granules India received its first US FDA approval for a Hyderabad facility in November 2025, enhancing its finished dosage manufacturing capabilities.

For Danish buyers sourcing Albendazole formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Standard terms in India-Denmark pharmaceutical trade often include letters of credit or advance payments; ensure terms are clearly defined to maintain cash flow efficiency.

• Supplier Qualification Process: Conduct thorough due diligence, including audits of manufacturing facilities, verification of WHO-GMP and US FDA certifications, and assessment of compliance histories.

• Regulatory Compliance: Ensure that selected suppliers have a proven track record of adhering to international regulatory standards to facilitate smooth importation and market acceptance in Denmark.